down arrow

Kezar Life Sciences, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US49372L1008
USD
6.25
0.1 (1.63%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

6.136.25

52 Week

3.537.25
Valuation
Technical
Day's Volume

CASH

23.62 k

Shareholding (Jun 2025)

FII

5.73%

Held by 31 FIIs

DII

76.21%

Held by 15 DIIs

Promoter

3.87%

How big is Kezar Life Sciences, Inc.?

22-Jun-2025

As of Jun 18, Kezar Life Sciences, Inc. has a market capitalization of 29.88 million, categorizing it as a Micro Cap company, with total assets of 144.68 million and shareholder's funds of 116.92 million. The company reported net sales of 0.00 million and a net profit of -78.64 million over the latest four quarters.

Market Cap: As of Jun 18, Kezar Life Sciences, Inc. has a market capitalization of 29.88 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, the sum of Net Sales is 0.00 million, while the sum of Net Profit amounts to -78.64 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the Shareholder's Funds are reported at 116.92 million, and the Total Assets stand at 144.68 million.

Read More

What does Kezar Life Sciences, Inc. do?

22-Jun-2025

Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for autoimmune disorders and cancer. It has a market cap of approximately $29.88 million and reported a net profit loss of $17 million as of March 2025.

Overview: <BR>Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company engaged in developing novel small molecule therapeutics to treat autoimmune disorders, cancer, and malignant diseases, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -17 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 29.88 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.99 <BR>Return on Equity: -74.87% <BR>Price to Book: 0.29<BR><BR>Contact Details: <BR>Address: 4000 Shoreline Ct Ste 300, SOUTH SAN FRANCISCO CA: 94080-2005 <BR>Tel: ['1 650 8225600', '1 212 2130006'] <BR>Fax: 1 302 6365454 <BR>Website: http://kezarlifesciences.com/

Read More

Who are in the management team of Kezar Life Sciences, Inc.?

22-Jun-2025

As of March 2022, the management team of Kezar Life Sciences, Inc. includes Dr. Jean-Pierre Sommadossi (Independent Chairman), Dr. Christopher Kirk (President and Chief Scientific Officer), and CEO John Fowler, along with several independent directors. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Kezar Life Sciences, Inc. includes the following individuals:<BR><BR>- Dr. Jean-Pierre Sommadossi, Independent Chairman of the Board<BR>- Dr. Christopher Kirk, President, Chief Scientific Officer, and Director<BR>- Mr. John Fowler, Chief Executive Officer and Director<BR>- Mr. Franklin Berger, Independent Director<BR>- Mr. Graham Cooper, Independent Director<BR>- Dr. Jason Dinges, Independent Director<BR>- Dr. Elizabeth Garner, Independent Director<BR>- Dr. Michael Kauffman, Independent Director<BR><BR>This team is responsible for guiding the company's strategic direction and overseeing its operations.

Read More

Is Kezar Life Sciences, Inc. technically bullish or bearish?

25-Jun-2025

As of June 2, 2025, the market trend is mildly bearish, indicated by mixed signals from the MACD and KST showing mild bullishness, while Bollinger Bands and daily moving averages reflect bearish trends.

As of 2 June 2025, the technical trend has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a combination of indicators. The MACD shows a mildly bullish signal on both the weekly and monthly time frames, while the KST also reflects a mildly bullish stance in the same periods. However, the Bollinger Bands indicate a bearish trend on the weekly and a mildly bearish trend on the monthly. The daily moving averages are bearish, and Dow Theory shows a bearish signal on the monthly with no trend on the weekly. Overall, the mixed signals suggest a lack of strong bullish momentum, reinforcing the mildly bearish outlook.

Read More

Is Kezar Life Sciences, Inc. overvalued or undervalued?

25-Jun-2025

As of November 12, 2024, Kezar Life Sciences, Inc. is considered overvalued and has deteriorated to a "does not qualify" rating due to poor financial metrics, including a negative ROE of -74.87% and a year-to-date stock performance of -36.61%, significantly underperforming the S&P 500.

As of 12 November 2024, the valuation grade for Kezar Life Sciences, Inc. has moved from risky to does not qualify, indicating a significant deterioration in its financial standing. The company is currently assessed as overvalued given its financial metrics, including a Price to Book Value of 0.31 and an EV to EBITDA ratio of 0.85. The negative ROE of -74.87% further underscores the challenges the company faces in generating returns for its shareholders.<BR><BR>In comparison to peers, Kezar Life Sciences, Inc. shows a less favorable position relative to CARA Therapeutics, Inc., which has a P/E ratio of -6.235, and Kodiak Sciences, Inc., also marked as does not qualify with a P/E of -0.9925. The company's recent stock performance has been underwhelming, with a year-to-date return of -36.61%, contrasting sharply with the S&P 500's gain of 2.44% over the same period. Overall, the combination of poor financial ratios and relative underperformance suggests that Kezar Life Sciences, Inc. is overvalued in the current market landscape.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 29 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.97

stock-summary
Return on Equity

-77.14%

stock-summary
Price to Book

0.32

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-14 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
60.67%
0%
60.67%
6 Months
42.37%
0%
42.37%
1 Year
-11.6%
0%
-11.6%
2 Years
-25.43%
0%
-25.43%
3 Years
-15.88%
0%
-15.88%
4 Years
-95.45%
0%
-95.45%
5 Years
-90.38%
0%
-90.38%

Kezar Life Sciences, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-36.08%
EBIT to Interest (avg)
-56.87
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.99
Sales to Capital Employed (avg)
0.04
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
82.21%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.31
EV to EBIT
0.84
EV to EBITDA
0.85
EV to Capital Employed
-47.45
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-74.87%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Sideways
Moving Averages
Bullish (Daily)
KST
Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Jun 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 22 Schemes (14.19%)

Foreign Institutions

Held by 31 Foreign Institutions (5.73%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 17.47% vs 17.82% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-14.40",
          "val2": "-17.40",
          "chgp": "17.24%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.30",
          "val2": "0.30",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-13.70",
          "val2": "-16.60",
          "chgp": "17.47%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -100.00% vs 0.00% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 17.86% vs -49.41% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "7.00",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-88.10",
          "val2": "-104.20",
          "chgp": "15.45%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.60",
          "val2": "1.50",
          "chgp": "6.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1.50",
          "val2": "-6.20",
          "chgp": "75.81%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-83.70",
          "val2": "-101.90",
          "chgp": "17.86%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-15,033.90%",
          "chgp": "1,503.39%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-14.40
-17.40
17.24%
Interest
0.30
0.30
Exceptional Items
0.00
0.00
Consolidate Net Profit
-13.70
-16.60
17.47%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 17.47% vs 17.82% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
7.00
-100.00%
Operating Profit (PBDIT) excl Other Income
-88.10
-104.20
15.45%
Interest
1.60
1.50
6.67%
Exceptional Items
-1.50
-6.20
75.81%
Consolidate Net Profit
-83.70
-101.90
17.86%
Operating Profit Margin (Excl OI)
0.00%
-15,033.90%
1,503.39%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -100.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 17.86% vs -49.41% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Kezar Life Sciences, Inc. stock-summary
stock-summary
Kezar Life Sciences, Inc.
Pharmaceuticals & Biotechnology
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing novel small molecule therapeutics to treat autoimmune disorders, cancer, and malignant diseases. Its therapies target protein homeostasis. Its lead development program is KZR-616. KZR-616 is a selective small molecule inhibitor of the immunoproteasome. Its second program focuses on small-molecule modulators of the protein secretion pathway. Its protein secretion program is focused on the areas of oncology, inflammation and immune-oncology.
Company Coordinates stock-summary
Company Details
4000 Shoreline Ct Ste 300 , SOUTH SAN FRANCISCO CA : 94080-2005
stock-summary
Tel: 1 650 82256001 212 2130006
stock-summary
http://kezarlifesciences.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."